Novacyt S.A.

("Novacyt", the "Company" or the "Group")

Result of AGM

Paris, France, and Manchester, UK - 30 June 2026 - Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces the results of voting on the resolutions at its Annual General Meeting ('AGM'), held today, as set out in the Notice of AGM.

All Ordinary Resolutions presented at the Ordinary General Meeting were passed and Resolutions 11, 12, 15, 16, 21, 23, 24 and 25 were passed from the Extraordinary General Meeting. Full details of the results of the AGM voting are available on the Company's website.

An investor presentation by Lyn Rees, Chief Executive Officer, and Steve Gibson, Chief Financial Officer, is now available on the Company's website and via the Investor Meet Company platform, with automated French subtitling https://novacyt.com/investors/presentations/

Lyn Rees, CEO of Novacyt, said: "We would like to thank our shareholders for their continued support and for the approval of our key financial resolutions allowing the Group to be agile should inorganic opportunities present themselves and accelerate the process to achieve EBITDA profitability. Our focus remains on streamlining our operations and reducing our cost base enabling us to achieve sustainable long-term growth for our shareholders."

Contacts

About Novacyt Group (www.novacyt.com)

Novacyt is an international molecular diagnostics company providing a broad portfolio of integrated technologies and services, primarily focused on the delivery of genomic medicine. The Company develops, manufactures, and commercialises a range of molecular assays and instrumentation to deliver workflows and services that enable seamless end-to-end solutions from sample to result across multiple sectors including human health, animal health and environmental.

The Company is divided into three business segments:

Novacyt is headquartered in Le Vésinet in France with offices in the UK (Manchester), Singapore, the US and Canada and has a commercial presence in over 65 countries, including Australia, following the recent acquisition of Southern Cross Diagnostics in March 2026, which has opened new distribution channels to the life sciences and diagnostics industries in the territory and the wider Asia-Pacific region.

The Company is listed on the London Stock Exchange's AIM market ("NCYT") and on the Paris Stock Exchange Euronext Growth ("ALNOV").

For more information, please refer to the website: www.novacyt.com